Lenarz T
Universitäts-HNO-Klinik Heidelberg.
Laryngorhinootologie. 1989 Nov;68(11):634-7. doi: 10.1055/s-2007-998418.
In a prospective randomised clinical study on 80 patients with idiopathic sudden hearing loss the therapeutic value of nimodipine was evaluated. Nimodipine is a 4-5-dihydropyridine calcium antagonist with selective spasmolytic and vasodilatory properties on cerebral vessels. The mean improvement of hearing (250, 500, 1000, 2000, 4000 Hz) amounted to 16.5 +/- 11.3 dB as compared with 18.6 +/- 10.2 dB achieved by standard treatment with hydroxyethyl starch (HAES) and naftidrofuryl. The difference is not significant (p greater than 0.2). These results together with the low rate of side effects indicate nimodipine as a therapeutic alternative in cases of hypertension, cardiac failure and allergic predisposition. The possible role of spontaneous recovery on one side and of specific parameters such as rheologic abnormalities or type of audiogram are discussed. They are important for a more sophisticated therapeutic approach towards sudden hearing loss.
在一项针对80例特发性突发性感音神经性听力损失患者的前瞻性随机临床研究中，评估了尼莫地平的治疗价值。尼莫地平是一种4-5-二氢吡啶类钙拮抗剂，对脑血管具有选择性解痉和血管舒张特性。与羟乙基淀粉（HAES）和萘呋胺酯标准治疗所达到的18.6±10.2 dB相比，听力（250、500、1000、2000、4000 Hz）的平均改善为16.5±11.3 dB。差异无统计学意义（p>0.2）。这些结果连同低副作用发生率表明，在高血压、心力衰竭和过敏体质的病例中，尼莫地平可作为一种治疗选择。讨论了自发恢复一方面的可能作用以及诸如血液流变学异常或听力图类型等特定参数的可能作用。它们对于更复杂的突发性听力损失治疗方法很重要。
